JP Morgan Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $40

Benzinga Newsdesk www.benzinga.com Positive 71.5%

Neg 0% Neu 0% Pos 71.5%

JP Morgan analyst Chris Schott maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Overweight and raises the price target from $35 to $40.